AKT1 and breast carcinoma: Rapamycin is widely regarded as an effective inhibitor of AKT/mTOR, which has been approved for the treatment of neuroendocrine tumors, breast cancer, kidney cancer, prostate intraepithelial neoplasia, et al. [8,9,10,11,12].